Arrowhead FY2025 revenue $829M on milestones; FDA approves first drug REDEMPLO

ARROWHEAD PHARMACEUTICALS, INC.

2025-FY EPS reported -$0.01 revenue$829,448,000

Revenue $829.4M in FY2025, up from $3.6M, driven by Novartis and Sarepta milestone payments.
FDA approved REDEMPLO (plozasiran) for FCS—first approved siRNA for the rare disease; self-administered quarterly.
Novartis licensing agreement for ARO-SNCA: $200M upfront, up to $2B milestones, low double-digit royalties.
Sarepta paid $300M milestones; $100M settled with cash and Arrowhead stock buyback at $18.79 per share.
Net loss attributable to Arrowhead: ($1.6M) vs ($599M) prior year; cash resources $919.4M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.